Regeneron Debt To Assets from 2010 to 2024
REGN Stock | USD 985.02 4.45 0.45% |
Debt To Assets | First Reported 2010-12-31 | Previous Quarter 0.08170749 | Current Value 0.13 | Quarterly Volatility 0.08325623 |
Check Regeneron Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regeneron main balance sheet or income statement drivers, such as Depreciation And Amortization of 442.1 M, Interest Expense of 76.7 M or Total Revenue of 13.8 B, as well as many exotic indicators such as Price To Sales Ratio of 6.79, Dividend Yield of 0.0 or PTB Ratio of 5.22. Regeneron financial statements analysis is a perfect complement when working with Regeneron Pharmaceuticals Valuation or Volatility modules.
Regeneron | Debt To Assets |
Latest Regeneron Pharmaceuticals' Debt To Assets Growth Pattern
Below is the plot of the Debt To Assets of Regeneron Pharmaceuticals over the last few years. It is Regeneron Pharmaceuticals' Debt To Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regeneron Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Debt To Assets | 10 Years Trend |
|
Debt To Assets |
Timeline |
Regeneron Debt To Assets Regression Statistics
Arithmetic Mean | 0.14 | |
Geometric Mean | 0.12 | |
Coefficient Of Variation | 58.35 | |
Mean Deviation | 0.06 | |
Median | 0.13 | |
Standard Deviation | 0.08 | |
Sample Variance | 0.01 | |
Range | 0.3053 | |
R-Value | (0.29) | |
Mean Square Error | 0.01 | |
R-Squared | 0.09 | |
Significance | 0.29 | |
Slope | (0.01) | |
Total Sum of Squares | 0.1 |
Regeneron Debt To Assets History
About Regeneron Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Regeneron Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Regeneron Pharmaceuticals investors use historical funamental indicators, such as Regeneron Pharmaceuticals's Debt To Assets, to determine how well the company is positioned to perform in the future. Although Regeneron Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Regeneron Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Regeneron Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Regeneron Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Regeneron Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Debt To Assets | 0.08 | 0.13 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Regeneron Pharmaceuticals Correlation against competitors. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share 33.88 | Revenue Per Share 122.574 | Quarterly Revenue Growth (0.01) | Return On Assets 0.0774 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.